Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELAVL1 | Q15717 | 7/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130644 | 0.86 | ELAVL1 (0.61) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL22130647 | 0.82 | ELAVL1 (0.54) | ELAVL1PTGS2ALOX5 | |
| SCHEMBL22130711 | 0.80 | ELAVL1 (0.54) | ELAVL1PTGS2ALOX5PTGS1HTR6 | |
| SCHEMBL22130729 | 0.77 | ELAVL1 (0.61) | ELAVL1PTGS2ALOX5HTR6L3MBTL1 | |
| SCHEMBL19737481 | 0.75 | ELAVL1 (1.00) | ELAVL1PTGS2ALOX5PTGS1HTR6 | |
| SCHEMBL22130645 | 0.74 | ELAVL1 (0.62) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL22130712 | 0.70 | ELAVL1 (0.55) | ELAVL1PTGS2ALOX5PTGS1HTR6 | |
| SCHEMBL22130646 | 0.70 | ELAVL1 (0.56) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL22130723 | 0.68 | ELAVL1 (0.58) | ELAVL1HTR6L3MBTL1 | |
| SCHEMBL22130669 | 0.68 | ELAVL1 (0.64) | ELAVL1PTGS2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | ELAVL1 2765/4885PTGS2 81/4885ALOX5 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.